Allogene Therapeutics announces CEO David Chang will present at the J.P. Morgan Healthcare Conference on January 15, 2025.
Quiver AI Summary
Allogene Therapeutics, Inc., a clinical-stage biotechnology company focused on developing allogeneic CAR T products for cancer and autoimmune diseases, announced that CEO David Chang will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, in San Francisco. The presentation will be available via live audio webcast on the company's website, with a replay accessible for 30 days afterward. Allogene aims to create “off-the-shelf” CAR T cell therapies to make cell therapy more accessible and reliable for patients. The press release includes caution regarding forward-looking statements related to development and commercialization risks associated with their innovative product candidates.
Potential Positives
- Allogene Therapeutics will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, increasing visibility among investors and industry stakeholders.
- The presentation will be accessible via a live audio webcast, providing an opportunity for broader audience engagement and transparency.
- The company showcases its commitment to innovation in cell therapy, specifically in developing “off-the-shelf” AlloCAR T™ products, which could improve accessibility for patients.
- David Chang, M.D., Ph.D., a recognized leader in the field, is representing the company, which can enhance credibility and confidence in Allogene's initiatives.
Potential Negatives
- The press release heavily emphasizes the risks associated with their novel technologies, indicating uncertainty in product development timelines, costs, safety, efficacy, and regulatory approval, which may undermine investor confidence.
- Allogene's acknowledgment of potential delays in commercialization due to factors outside their control suggests vulnerability in their business strategy, particularly as they are a clinical-stage company.
FAQ
What event will Allogene Therapeutics participate in?
Allogene Therapeutics will present at the 43rd Annual J.P. Morgan Healthcare Conference.
When is the presentation scheduled?
The presentation is scheduled for January 15, 2025, at 3:00 PM PT / 6:00 PM ET.
Where can I access the presentation?
The presentation will be available via a live audio webcast on Allogene's website under the Investors tab.
How long will the presentation replay be available?
A replay of the presentation will be available for approximately 30 days on Allogene's website.
What is Allogene Therapeutics known for?
Allogene Therapeutics is known for pioneering allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALLO Insider Trading Activity
$ALLO insiders have traded $ALLO stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ALLO stock by insiders over the last 6 months:
- DEBORAH M. MESSEMER has traded it 2 times. They made 0 purchases and 2 sales, selling 27,777 shares.
- FRANZ B HUMER sold 9,221 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALLO Hedge Fund Activity
We have seen 70 institutional investors add shares of $ALLO stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LYNX1 CAPITAL MANAGEMENT LP added 3,974,079 shares (+178.3%) to their portfolio in Q3 2024
- BOXER CAPITAL, LLC removed 3,850,000 shares (-100.0%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 2,593,091 shares (+106.0%) to their portfolio in Q3 2024
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,343,724 shares (+461.6%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 1,327,063 shares (+8.1%) to their portfolio in Q3 2024
- FMR LLC removed 1,230,644 shares (-3.9%) from their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC removed 1,105,946 shares (-63.3%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene, will present at the 43rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco.
43
rd
Annual J.P. Morgan Healthcare Conference
Wednesday, January 15, 2025
3:00PM PT/ 6:00PM ET
A live audio webcast of the presentation will be made available on the Company's website at
www.allogene.com
under the Investors tab in the News and Events section.
Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T
™
) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit
www.allogene.com
, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
[email protected]
